Kidney Cancer (@IntKidneyCancer) header
Kidney Cancer (@IntKidneyCancer) profile picture

We talk about research, studies, trials, therapies, medical doctors and specialist centers in the world. WE WANT TO GIVE CONCRETE SUPPORT TO PATIENTS

Italia
Joined August 2024
Good morning everyone this is the link of the Italian Kidney Cancer group ❤️ Athos MANDRELLI facebook.com/share/g/5Cg4XCH…
1
2
983
RCC that recurs after adjuvant atezolizumab has different RNA signatures than RCC after placebo. IMmotion010: 🧬 Placebo arm: more B cell and macrophage signatures 🧬 Atezolizumab arm: lower MHC-I, which presents tumor antigen to T cells 🔍 80 of 754 had recurrence tissue Lower MHC-I argues for a VEGF-based next line over more IO. Still hypothesis-generating. 🧪 Testing a HIF-2α inhibitor + VEGF TKI after IO: PEAK-1, LITESPARK-033, LITESPARK-034 👉 bit.ly/Xu-IMmotion010 @montypal @brian_rini #KidneyCancer #RCC #GUonc
3
7
16
1,229
Kidney Cancer retweeted
Important point from the panel: None of the 3 belzutifan trials in adjuvant or advanced RCC have demonstrated a statistically significant OS benefit. Shared decision-making is especially critical in adjuvant ccRCC. Patient-reported long-term toxicity data should inform these discussions. STRIKE (Alliance A032201) remains open for enrollment. @BradMcG04 #UromigosLive #uromigos
9
26
1,304
Kidney Cancer retweeted
Triplets in 1st line RCC failed in LS12 @Annals_Oncology @brian_rini (n=1500!). There are not many combinations with HIF/VEGF/PD1 left to test and this approach has probably run its course. It’s time for a new chapter in RCC with T cell engagers and bispecifics #ESMO26 @montypal @DrChoueiri @OncoAlert
5
20
2
65
4,308
Kidney Cancer retweeted
Discussing Treatment Strategies After Adjuvant Immunotherapy for RCC at EMUC 2026 - Roberto Iacovelli (@DrIacovelli) oncodaily.com/voices/roberto…
3
6
230
Kidney Cancer retweeted
Alternating Pazopanib and Bevacizumab in Treatment-Naive Metastatic ccRCC: Phase 1/2 Trial Results A multicentre, single-arm phase 1/2 trial evaluated alternating pazopanib and bevacizumab in metastatic clear-cell renal cell carcinoma (ccRCC), with 51 treatment-naive patients evaluable for efficacy. Key findings: ▫️ Median PFS: 24.8 months (95% CI 17.2–34.3), with a 12-month PFS rate of 73%. ▫️ Median OS: 63.2 months (95% CI 47.6–96.6). ▫️ ORR (post-hoc): 55%, including 4% complete responses. ▫️ Favourable-risk subgroup: Median PFS of 28.5 months and OS of 76.9 months. ▫️ Safety (n=59): Grade 3–4 hypertension (34%), ALT elevation (17%), and AST elevation (12%). No treatment-related deaths occurred. Takeaway: Alternating pazopanib and bevacizumab showed promising antitumour activity in treatment-naive metastatic ccRCC, in a predominantly favourable-risk population. Randomised phase 3 trials are needed to establish its efficacy and safety relative to current first-line therapies. @Dr_SabyGeorge @DrVaishampayan @OncoDailyGI oncodaily.com/genitourinary-… #OncoDaily #OncoDailyGU
5
11
258
Kidney Cancer retweeted
New in @TheLancetOncol : outcomes for patients with #RCC brain metastases are changing. In 1,049 patients, median OS was 20 months—up from 9.6–12 months in historical cohorts. Updated Renal GPA predicts survival from 4.8 to 51.2 months. Important message: brain metastases should not automatically exclude patients from clinical trials. Proud to contribute to this international effort led by Paul Sperduto and Minesh Mehta. thelancet.com/journals/lanon… @RifRahmanMD @SanjayAnejaMD @Luke_Pike_MD @TonyWangMD @SteveBraunstein @TugceKutukMD @Rrkotecha @DukeCancer @DukeRadOnc @MiamiCancerInst @BaptistHealthSF
4
44
2
109
8,818
🇪🇸 #ESMO26, one week later... What’s Up about #RCC?? 📈 Still strong benefit with adjuvant pembro therapy! @DrChoueiri @CPRT65 @tompowles1 💉 Vaccines towards advRCC @BraunMDPhD ➡️ Challenges for ADCs in RCC: the barriers @YujiMiura5 ☢️ The optimal management of Oligo-RCC @ShankarSiva @DrIacovelli 🧬 Proteogenomics, metastatic patterns, and future therapeutic vulnerabilities 💊 @FudanUniversity And Litespark 011, 012, Care 1, Rampart, XmAb819… @myESMO @OncoAlert @IKCCorg @KidneyCancer @kcCURE @kidneycan
1
9
19
1,419
Kidney Cancer retweeted
Several groups have attempted to predict the IM151 RCC clusters with flawed methods. We developed IRIS-RCC (Individual RNA-seq Intrinsic Subtyping for RCC; available at irisrcc.vindhyadatascience.c…), to predict clusters using an individual-sample model. nature.com/articles/s41698-0…
3
17
6
63
8,960
Kidney Cancer retweeted
🚀 Is GU oncology becoming one of the most exciting fields for molecular imaging & theranostics? PSMA in prostate cancer, CAIX in clear-cell RCC, and emerging NECTIN4-targeted approaches in urothelial cancer! Fantastic to see CAIX imaging on the cover of The Lancet Medical Imaging & Theranostics. CAIX is a particularly elegant target: VHL loss → HIF stabilization → CAIX upregulation in ccRCC. Using tumor biology wisely! 🧬 The opportunity goes beyond detecting disease: molecular imaging could enable patient selection, visualize target heterogeneity and potentially guide radioligand therapy. Of course, CAIX-directed theranostics still require prospective validation, particularly of therapeutic efficacy and safety. Exciting times for precision GU oncology! 👏 Read here: sciencedirect.com/science/ar… @ProfKHerrmann #KidneyCancer #Theranostics #GUOncology @weoncologists @urotoday @Uromigos @OncoAlert and Faculty: @DrChoueiri @tompowles1 @apolo_andrea @neerajaiims @montypal @Silke_Gillessen @AOmlin @brian_rini @PGrivasMDPhD @TiansterZhang @amerseburger @DrDanielHeng @HHammersMD @scocmem @AndreaNecchi @AmandaNizamMD @drenriquegrande @nataliagandur @AlbigesL @cdanicas @declangmurphy @seanmmcbride @shilpaonc @DrRanaMcKay @scserendipity1 @DrYukselUrun @ravikanesvaran @BraunMDPhD @EfstathiouEleni @mzugman @crisbergerot @Markuseckstein3
2
23
2
68
3,677
Kidney Cancer retweeted
One tumor sample, without needing a reference cohort. 🧬🔬 IRIS-RCC uses within-sample gene expression ratios to classify metastatic clear cell RCC into molecular groups, addressing a hurdle in translating tumor subtyping into practice. 📊 87% cross-validation accuracy 🧪 Validated in JAVELIN Renal 101 data 🎯 Subtypes associated with distinct treatment outcomes 👇 How it works, and why biopsy site matters: oncologynexus.com/researcher… @brian_rini @VUMCDiscoveries @DrScottHaake @Vindhya_DS @katy_beckermann
4
2
256
Kidney Cancer retweeted
These data are very relevant in advanced RCC, in this age of immunotherapy. Thanks to all the co-investigators, coordinators, the respective institutional ethics committees at 5 centers and above all, to the patients. @deepak_kilari @LenAppleman @DrVaishampayan @EHeath4100
In a clinical trial just published in The Lancet Oncology, researchers led by Dr. Saby George reported promising results from combining the targeted cancer drugs bevacizumab (Avastin) and pazopanib (Votrient). Read more: roswellpark.org/newsroom/202…
2
1
7
945
Kidney Cancer retweeted
Proud to report at #ESMO2026 the results of PE-PE trial. Oligometastatic #RCC pts have a significant benefit when pembro was added to MDT irrespectively of the type of MDT used and up to 5y from previous surgery. Thanks to the 🇮🇹 team and special thanks to @DrChoueiri! @OncoAlert @urotoday @myESMO @KidneyCancer @Sebastiano_Buti @ciccarese_c @fmassari79 @mimma_rizzo @elena_verzoni @MatteoSantoniMD
24
2
68
4,660
Kidney Cancer retweeted
Well well well… This was certainly my favorite RCC / kidney cancer presentation and heralding a significant shift in the RCC landscape! 45% response in heavily pretreated pts. Highly impressive! Needs to move into frontline combinations! Congrats @montypal + colleagues
1
24
6
67
9,728
🚨⭐ #ESMO26 | IUCS GU ONCOLOGY — DAY 3 HIGHLIGHTS 🟢 Kidney cancer took center stage today, with pivotal phase III readouts, mature adjuvant follow-up and a promising new immune target. 📊 1️⃣ LITESPARK-012 | 3586O ❌ In 1L advanced ccRCC, neither adding belzutifan nor CTLA-4 blockade (quavonlimab) to pembrolizumab + lenvatinib improved PFS or OS. * Belzutifan triplet: median PFS 20.8 vs 23.7 months (HR 1.08). * More treatment discontinuations due to adverse events. Clinical lesson: a triplet is not necessarily better than an effective doublet. 📊 2️⃣ LITESPARK-011 | 3587O ✅ After anti–PD-(L)1 therapy, belzutifan + lenvatinib maintained a PFS benefit vs cabozantinib: * Median PFS 14.8 vs 10.8 months | HR 0.74 * ORR 53.1% vs 40.2% ⚠️ Final OS: 33.7 vs 28.6 months | HR 0.85; did not meet the prespecified significance boundary. The combination offers an additional option, but sequencing and tolerability are key. 📊 3️⃣ KEYNOTE-564 | 3589RO ✅ Final planned analysis confirms durable benefit from adjuvant pembrolizumab in high-risk ccRCC after nephrectomy: * 7-year DFS 57.2% vs 44.6% | HR 0.68 * 7-year OS 82.3% vs 76.6% | HR 0.70 An established standard backed by long-term disease-free AND overall survival data. 🧬 4️⃣ XmAb819 | 3588O A first-in-class ENPP3 × CD3 T-cell engager showed confirmed response rates of ~30–46% across phase I expansion dose groups in heavily pretreated ccRCC. ⚠️ Early evidence; grade ≥3 treatment-related adverse events occurred in 72% of expansion patients. Randomized validation is essential. 🔬 5️⃣ RAMPART | 3590RO Patient-reported outcomes highlighted early quality-of-life trade-offs with adjuvant durvalumab versus active monitoring—an important reminder that efficacy and lived experience both matter. ⭐ IUCS CLINICAL TAKEAWAY Today delivered a powerful contrast: negative frontline triplets, meaningful post-immunotherapy PFS benefit, and durable adjuvant survival benefit. 💡 Precision is not about adding more agents. It is about choosing the right strategy, at the right stage, with the right balance of benefit and toxicity. @gbanna74 @ravikanesvaran @nataliagandur @neerajaiims @Sebastiano_Buti @CinziaConted @dralishadamani @amg120395 @PGrivasMDPhD @koshkin85 @MicheleMaffezz @ParamMariappan @dmukherji @VanitaNoronha @montypa @DanieleRaggi83 @PasRescigno @jteoh_hk @alison_tree @DrYukselUrun @yekeduz_emre @AgrawalTrush @AndrewKevinAlo1 @ONCOassist @VuMedi @ProstateUK @OncologyNT @OncJournal #IUCS #ESMO26 #GUOncology #KidneyCancer #RCC #PrecisionOncology
8
1
13
771
Can personalized vaccines help prevent kidney cancer recurrence? At #ESMO26, Prof. David Braun @BraunMDPhD discusses early Phase 1 findings in high-risk ccRCC and future combination strategies. Watch the full interview. #RenalCellCarcinoma #KidneyCancer #Immunotherapy
1
1
50
Kidney Cancer retweeted
Can a biomarker help guide treatment selection for advanced kidney cancer? New findings from the phase 3 COSMIC-313 trial, presented by @VincentWenxinXu, MD, support the potential of KIM-1 to identify patients with advanced clear cell renal cell carcinoma who may benefit from immunotherapy alone versus immunotherapy plus cabozantinib. These findings advance efforts to use biomarkers to guide more personalized treatment strategies for kidney cancer. #ESMO26
4
22
1,645
Replying to @RicBertolo
@RicBertolo, specialista in #urologia, ci accompagnerà lungo il percorso del paziente con carcinoma renale, mostrando come il ruolo dell’urologo si estenda ben oltre l’intervento chirurgico, dalla definizione del percorso di cura all’integrazione delle diverse competenze coinvolte. L’urologo rappresenta oggi la figura chiave per garantire continuità di cura e accompagnare il paziente in ogni fase del suo percorso. #SIUtalkScienza
2
5
216
Kidney Cancer retweeted
⚡️ LITESPARK-011 final analysis #ESMO26: belzutifan + lenvatinib vs cabozantinib in advanced ccRCC after anti–PD-(L)1 therapy. PFS HR 0.74 (14.8 vs 10.8 mo). ORR 53% vs 40%. OS HR 0.85 — not statistically significant. PFS and ORR benefits maintained at final analysis. @DrDanielHeng @OncoAlert #KidneyCancer #ESMO26 #GUOncology oncodaily.com/genitourinary-…
5
13
1
17
1,282
Kidney Cancer retweeted
Thank you to @tompowles1 for asking the question and to The @Uromigos and @shilpaonc for this very important conversation about Upper Tract Urothelial Carcinoma. Yes to a trial and yes to well-considered options for UTUC patients while we wait! It does my heart good to see this complex disease get continued attention post POUT. creators.spotify.com/pod/pro…
It looks like we’re not sure about the best systemic approach to upper tract urothelial cancer. Data for nivolumab in Upper tract disease is not great (DFS HR- 1.23 (0.67-2.23), while the carboplatin subset of POUT was also underwhelming (OS HR 0.87: 0.50-1.53). ctDNA appeared to work for UTUC in IM010 but was excluded in IM011 due to concerns from the nivo data in this subgroup. EVP has always beaten everything else in UC, and upper tract subsets of 302 looked good - but there in no adjuvant data. What to do? I’m not sure. In ctDNA positives I might be tempted to go with EVP and survey the -ves (and give EVP if they relapse), but it feel a long way off piste! @MattGalsky @OncoAlert @montypal @DrChoueiri @AlisonBirtle
1
5
5
1,176
Kidney Cancer retweeted
⚡️ Phase 2 trial in RCC with inferior vena cava tumor thrombus: neoadjuvant stereotactic ablative radiotherapy (SAbR) followed by surgery (n=23). 1-year recurrence-free survival: 71.4% — above the 55.7% historical benchmark. Thrombus downstaging in 22%. A promising approach for one of the most challenging complications in kidney cancer. #KidneyCancer #RCC @JAMAOnc jamanetwork.com/journals/jam…
1
32
1
53
4,326